Sanofi wants to reduce the time, cost, and bias involved in drug discovery, where researchers must evaluate vast numbers of compounds and need richer disease, protein, molecule, clinical, and real-world data to support AI-driven research.
Reported impact
Sanofi aims to accelerate pharmaceutical research, better understand biology, identify the right molecules faster, and deliver therapies to patients more quickly by applying AI and machine learning to drug discovery.
Sanofi describes an in-house AI and machine-learning approach for drug R&D that combines broad scientific and clinical data collection with modeling and simulation workflows. The implementation centers on building high-quality, diverse data foundations for disease biology, protein interactions, molecule behavior, and patient outcomes so AI models can be used in discovery. Sanofi says its teams integrate bioinformatics and omics data with inputs from smart devices and wearables used in decentralized clinical trials, then expand internal data libraries with patient data from clinical trials and real-world datasets. Those datasets are used to discover and validate digital biomarkers, study small and large molecules, and support faster candidate selection. Cross-functional research, development, and digital teams operate the workflow, while collaborations with Owkin, Exscientia, Atomwise, and Insilico Medicine extend Sanofi's discovery efforts.
Sanofi aggregates disease, protein, molecule, clinical-trial, real-world, bioinformatics, omics, smart-device, and wearable data into growing internal data libraries. AI and machine-learning models run on those curated datasets to identify digital biomarkers, analyze small and large molecules, and accelerate drug-discovery decisions.
"By leveraging bioinformatics and omics data along with smart devices and wearables used in decentralized clinical trials, they are bolstering their growing data libraries."
"By leveraging their collaborations with partners like Owkin, Exscientia, Atomwise, and Insilico Medicine, they are already working to develop new ways to accelerate drug discovery and ultimately benefit patients more quickly."
"Researchers must navigate through an infinite number of compound possibilities before designing the best option."
"Sanofi is working to address this need for more data with its internal processes to achieve a more comprehensive integration of high-quality, diverse data, to enable the use of AI models in drug discovery."
"With appropriate data and AI models, this process could be accelerated dramatically, saving valuable time and resources and eliminating the bias that comes with human trial and error."
Review how this reference was scored and trace each normalized claim back to its documented source.
Scoring methodology
Customer Reference Value measures usefulness as a customer reference. Evidence Confidence measures the quality and traceability of available evidence, not independent verification.
Traceability
Field coverage shows which facts each source supports. Dates are shown only when documented by the source.
Sanofi has moved into its new global headquarters in the 17th arrondissement of Paris, at 46-48 Avenue de la Grande Armée.
Related
In-house Sample Jul 28, 2026 Novartis Novartis R&D needs to turn large volumes of scientific, clinical, operational, and real-world data into faster, higher-quality decisions across drug discovery and development, reducing cycle times, surfacing safety… less than 10 percent of drug candidates historically reach the market AI models · AI-enhanced analytics · Generative AI In-house Sample Apr 13, 2026 Elevance Health Elevance Health needed to find fraud, waste, and abuse in very large volumes of claims, payment, contract, and medical-record data so it could detect billing errors, suspicious coding patterns, and improper payments… across an annualized volume of nearly 23,000 reviews In-house Sample Feb 24, 2026 Sanofi Sanofi needed a faster, more objective way to decide which R&D programs to advance, accelerate, or stop while weighing costs, clinical trial enrollment timelines, unmet need, competition, and each program's probability… more than one billion data points across Sanofi Aily Labs · Plai 